DEP irinotecan synergistic with Lynparza in refractory model
Filed with ASX · · 4 pages · English
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- VivaGel BV regulatory approvals continue in Asia
- Positive results with Targeted DEP using antibody fragment
- Promising efficacy signals observed in ongoing DEP trials
- First Asian Regulatory Approvals Received for VivaGel BV
- Starpharma commences phase 1/2 DEP irinotecan trial
Later from Starpharma
- FDA Authorises Clinical Trial with AstraZeneca DEP product
- DEP outperforms Gemzar in human pancreatic cancer model
- UK launch of VivaGel BV
- VivaGel condom receives regulatory approval in Europe
- AGM - Chairman address and CEO presentation
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma